The company said in earnings presentation slides: “Feedback from FDA confirmed need for flu vaccine efficacy data; expect review timeline to be extended; now targeting 2026 approval.” This refers to mRNA-1083, which is targeting Flu plus COVID in patients 50 years old and older. Shares of Moderna (MRNA) are down 3%, or 88c, to $27.66 in late morning trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Trump Trade: RFK Jr. invests $500M in universal vaccine project
- MRNA Earnings: Moderna Stock Catches a Cold as More ‘Normal’ Covid Hits Revenues
- MRNA Earnings: Shares Slump as Moderna Reveals Covid Hit to Revenues
- Mixed Financial Performance and Pipeline Progress Lead to Hold Rating on Moderna
- Moderna reports Q1 EPS ($2.52), consensus ($3.18)